HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

[Immune response to biological therapy of inflammatory bowel diseases].

AbstractAIM:
To study biological (cell and anticytokine) therapy-induced changes in the levels of proinflammatory cytokines in patients with inflammatory bowel diseases (IBD).
SUBJECTS AND METHODS:
Forty-four patients with chronic continuous or chronic recurrent IBD were examined. According to the performed therapy, the patients were divided into 3 groups: 1) 16 patients who took infliximab; 2) 14 patients who received combination anti-inflammatory therapy with the cultured mesenchymal stromal cells (MSC) being administered; 3) 14 patients who had standard anti-inflammatory therapy with 5-aminosalycilic acid preparations and glucocorticosteroids. The concentrations of tumor necrosis factor-alpha (TNF-alpha), interferon-gamma (INF-gamma), and interleukins (IL)-2, -5, -8, -12, and -15 were determined in the patients' sera before and 2 months after therapy initiation.
RESULTS:
The elevation in the serum levels of the proinflammatory cytokines TNF-alpha, INF-gamma, and IL-2, -5, -8, -12, and -15 indicates their implication in the pathogenesis of ulcerative colitis and Crohn's disease. Their levels may evaluate both the activity of an inflammatory process and the efficiency of the therapy. The higher level of these cytokines is accompanied by the enhanced activity of diseases, which may be used to diagnose their activity, to predict the course of IBD, and to perform adequate therapy. The decreased level of the proinflammatory cytokines is indicative of the efficiency of the therapy in patients with IBD.
CONCLUSION:
By reducing TNF-alpha levels, infliximab therapy results in a decrease in the concentrations of other proinflammatory cytokines (IL-1, -2, -5, -8), thus lowering the inflammatory activity of IBD. MSC transplantation also reduces the level of most proinflammatory cytokines, thus diminishing the intensity of immunopathological processes, which is shown by positive changes in the clinical picture of the disease.
AuthorsO V Kniazev, A I Parfenov, I N Ruchkina, L B Lazebnik, V É Sagynbaeva
JournalTerapevticheskiĭ arkhiv (Ter Arkh) Vol. 85 Issue 12 Pg. 55-9 ( 2013) ISSN: 0040-3660 [Print] Russia (Federation)
PMID24640669 (Publication Type: Clinical Trial, Comparative Study, English Abstract, Journal Article)
Chemical References
  • Anti-Inflammatory Agents, Non-Steroidal
  • Antibodies, Monoclonal
  • Cytokines
  • Glucocorticoids
  • Mesalamine
  • Infliximab
Topics
  • Adolescent
  • Adult
  • Aged
  • Anti-Inflammatory Agents, Non-Steroidal (therapeutic use)
  • Antibodies, Monoclonal (administration & dosage)
  • Chronic Disease
  • Cytokines (adverse effects, antagonists & inhibitors, biosynthesis)
  • Female
  • Glucocorticoids (therapeutic use)
  • Humans
  • Inflammatory Bowel Diseases (drug therapy, immunology, therapy)
  • Infliximab
  • Male
  • Mesalamine (therapeutic use)
  • Mesenchymal Stem Cell Transplantation (methods)
  • Middle Aged
  • Primary Cell Culture
  • Secondary Prevention
  • Treatment Outcome
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: